Intratumoral Cancer Therapies Market
Key Findings:
- In 2021, the total intratumoral cancer therapies market size was approximately USD 93 million which is expected to rise during the study period (2019–2032).
- In 2021, the total Intratumoral Cancer patient pool cases across 7MM were about 469 K which are expected to grow during the study period, i.e., 2019–2032.
Request a sample to unlock the CAGR for Intratumoral Cancer Therapies Market.
DelveInsight's "Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Intratumoral Cancer Therapies, historical and forecasted epidemiology as well as the Intratumoral Cancer Therapies market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Intratumoral Cancer Therapies market report provides current treatment practices, emerging drugs, Intratumoral Cancer Therapies market share of the individual therapies, current and forecasted Intratumoral Cancer Therapies market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Intratumoral Cancer Therapies treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Intratumoral Cancer Therapies market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Intratumoral Cancer Therapies Disease Understanding and Treatment Algorithm
The DelveInsight’s Intratumoral cancer therapies epidemiology report gives a thorough understanding of Intratumoral (IT) cancer therapies by including details such as overview of Intratumoral Cancer Therapies, advantages, disadvantages and available therapies. Comprehensive epidemiology insight of the tumors targeted by Intratumoral Cancer Therapies. IT therapy refers to any therapy that is delivered in very close anatomical proximity to a tumor with the intention of direct uptake by tumors or tumor cells. It is a therapeutic strategy which aims to use the tumor as its own vaccine.
Using tumor as a source of antigens expressed across multiple tumor clones, IT immunotherapies aim to initiate local recruitment of immune cells into the tumor microenvironment and subsequently prime T cells for a systemic polyclonal antitumor response (abscopal effect), potentially addressing intra and inter-tumoral heterogeneity.
Many cancers are not inflamed (“cold”) and thus, are not recognized by the immune system, intratumoral (IT) approach is one such approach where pharma company trying to turn “cold” tumors to “hot” that shows signs of inflammation so that they can be infiltrated with T cells, working to fight the cancer. These tumors are easier to treat, as immunotherapy drugs can boost up the immune response.
There are different categories of intratumoral therapies: cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules. Currently, only three intratumoral therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US, Europe and Japan in 2015, DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) approved in Japan in 2021 and HENSIFY (Nanobiotix) approved in European market in 2019.
Intratumoral Cancer Therapies Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Intratumoral Cancer Therapies.
Intratumoral Cancer Therapies Treatment
It covers the details of conventional and current medical therapies available in the Intratumoral Cancer Therapies market for the treatment of the condition. It also provides Intratumoral Cancer Therapies treatment algorithms and guidelines in the United States, Europe, and Japan.
Intratumoral Cancer Therapies Epidemiology
The Intratumoral Cancer Therapies epidemiology section provides insights about the historical and current Intratumoral Cancer Therapies patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Intratumoral Cancer Therapies market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Intratumoral Cancer Therapies Key Findings
The Intratumoral Cancer epidemiology covered in the report provides historical as well as forecasted intratumoral cancer therapies epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In 2021, the total Intratumoral Cancer patient pool cases across 7MM were about 469 K which are expected to grow during the study period, i.e., 2019–2032.
The disease epidemiology covered in the report provides historical as well as forecasted intratumoral cancer therapies epidemiology [segmented as Total Incident cases of selected cancer types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma), Target patient Pool of intratumoral therapies by Cancer Types and Treated cases by Cancer Types] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Intratumoral Cancer Therapies Epidemiology
The epidemiology segment also provides the Intratumoral Cancer Therapies epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Intratumoral Cancer Therapies Drug Chapters
The drug chapter segment of the Intratumoral Cancer Therapies report encloses the detailed analysis of Intratumoral Cancer Therapies marketed drugs and late-stage (Phase-III and Phase-II) Intratumoral Cancer Therapies pipeline drugs. It also helps to understand the Intratumoral Cancer Therapies clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Intratumoral Cancer Therapies Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Intratumoral Cancer Therapies treatment.
Intratumoral Cancer Therapies Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Intratumoral Cancer Therapies treatment.
Intratumoral Cancer Therapies Market Outlook
The Intratumoral Cancer Therapies market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Intratumoral Cancer Therapies market trends by analyzing the impact of current Intratumoral Cancer Therapies therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Intratumoral Cancer Therapies market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Intratumoral Cancer Therapies market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Intratumoral Cancer Therapies market in 7MM is expected to witness a major change in the study period 2019-2032.
Intratumoral Cancer Therapies Key Findings
The intratumoral cancer therapies market size in the 7MM is expected to change during the study period 2019–2032. The intratumoral cancer therapies therapeutic market in the seven major markets is expected to increase during the study period (2019–2032).
In 2021, the total intratumoral cancer therapies market size was approximately USD 93 million which is expected to rise during the study period (2019–2032).
The United States: Intratumoral Cancer Therapies Market Outlook
The total intratumoral cancer therapies market size in the United States accounted for USD 21 million in 2021 which is expected to rise during the study period (2019–2032).
EU-5 Countries: Intratumoral Cancer Therapies Market Outlook
In EU5, the total intratumoral cancer therapies market size was USD 22 million in 2021, which is expected to rise during the study period (2019–2032).
Japan: Intratumoral Cancer Therapies Market Outlook
In Japan, the total intratumoral cancer therapies market size was USD 0.2 million in 2021, which is expected to rise during the study period (2019–2032).
Intratumoral Cancer Therapies Drugs Uptake
This section focuses on the rate of uptake of the potential Intratumoral Cancer Therapies drugs recently launched in the Intratumoral Cancer Therapies market or expected to get launched in the market during the study period 2019-2032. The analysis covers Intratumoral Cancer Therapies market uptake by drugs; patient uptake by therapies; and sales of each drug.
Intratumoral Cancer Therapies Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Intratumoral Cancer Therapies market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Intratumoral Cancer Therapies Pipeline Development Activities
The Intratumoral Cancer Therapies report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Intratumoral Cancer Therapies key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Intratumoral Cancer Therapies report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Intratumoral Cancer Therapies emerging therapies.
Reimbursement Scenario in Intratumoral Cancer Therapies
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current Intratumoral Cancer Therapies market trends, we take KOLs and SMEs ' opinion working in the Intratumoral Cancer Therapies domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Intratumoral Cancer Therapies market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Intratumoral Cancer Therapies Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
|
Report Metrics |
Details |
|
Study Period |
2019 to 2032 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2032 |
|
CAGR |
|
|
Market Size |
USD 93 million in 2021 |
|
Key Companies |
Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp & Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals, Sirnaomics, Apexigen, Replimune, Merck & Co (Viralytics), Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix |
Scope of the Intratumoral Cancer Therapies Report
- The report covers the descriptive overview of Intratumoral Cancer Therapies, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Intratumoral Cancer Therapies epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Intratumoral Cancer Therapies is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Intratumoral Cancer Therapies market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Intratumoral Cancer Therapies market
Intratumoral Cancer Market Report Highlights
- In the coming years, the Intratumoral Cancer Therapies market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Intratumoral Cancer Therapies R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Intratumoral Cancer Therapies. The launch of emerging therapies will significantly impact the Intratumoral Cancer Therapies market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Intratumoral Cancer Therapies
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Intratumoral Cancer Therapies Report Insights
- Intratumoral Cancer Therapies Patient Population
- Intratumoral Cancer Therapeutic Approaches
- Intratumoral Cancer Therapies Pipeline Analysis
- Intratumoral Cancer Therapies Market Size
- Intratumoral Cancer Therapies Market Trends
- Intratumoral Cancer Therapies Market Opportunities
- Impact of upcoming Intratumoral Cancer Therapies Therapies
Intratumoral Cancer Therapies Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Intratumoral Cancer Therapies Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Intratumoral Cancer Therapies Market
- Intratumoral Cancer Drugs Uptake
Intratumoral Cancer Therapies Report Assessment
- Current Treatment Practices
- Intratumoral Cancer Therapies Unmet Needs
- Intratumoral Cancer Therapies Pipeline Product Profiles
- Intratumoral Cancer Therapies Market Attractiveness
- Intratumoral Cancer Therapies Market Drivers
- Intratumoral Cancer Therapies Market Barriers
Key Questions
Intratumoral Cancer Therapies Market Insights:
- What was the Intratumoral Cancer Therapies drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Intratumoral Cancer Therapies total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Intratumoral Cancer Therapies market size during the forecast period (2019-2032)?
- At what CAGR, the Intratumoral Cancer Therapies market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Intratumoral Cancer Therapies market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Intratumoral Cancer Therapies market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Intratumoral Cancer Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Intratumoral Cancer Therapies?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Intratumoral Cancer Therapies patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Intratumoral Cancer Therapies in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Intratumoral Cancer Therapies?
- Out of all 7MM countries, which country would have the highest prevalent population of Intratumoral Cancer Therapies during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Intratumoral Cancer Therapies treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Intratumoral Cancer Therapies in the USA, Europe, and Japan?
- What are the Intratumoral Cancer Therapies marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Intratumoral Cancer Therapies?
- How many therapies are in-development by each company for Intratumoral Cancer Therapies treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Intratumoral Cancer Therapies treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Intratumoral Cancer Therapies therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Intratumoral Cancer Therapies and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Intratumoral Cancer Therapies?
- What are the global historical and forecasted market of Intratumoral Cancer Therapies?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Intratumoral Cancer Therapies market
- To understand the future market competition in the Intratumoral Cancer Therapies market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Intratumoral Cancer Therapies in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Intratumoral Cancer Therapies market
- To understand the future market competition in the Intratumoral Cancer Therapies market
Frequently Asked Questions
1. Key Insights
2. Report Introduction
3. Intratumoral cancer therapies Market Overview at a Glance
3.1. Market Share (%) Distribution of Intratumoral cancer therapies in 2019: By Country
3.2. Market Share (%) Distribution of Intratumoral cancer therapies in 2032: By Country
3.3. Market Share (%) Distribution of Intratumoral cancer therapies in 2025: By Indication
3.4. Market Share (%) Distribution of Intratumoral cancer therapies in 2032: By Indication
4. Key Highlights from Report
5. Executive Summary of Intratumoral cancer therapy
5.1. Key Events
6. Epidemiology and Market Forecast Flow
7. Background and Overview
7.1. Introduction
7.2. Types of Cancer Therapy
7.3. Intratumoral Therapies
7.4. History of Intratumoral Therapies
7.5. Mechanism of Intratumoral Therapies
7.6. Principles of Intratumoral Immunotherapy
7.6.1. In Situ priming of antitumor immunity
7.6.2. Use the tumor as its vaccine
7.6.3. Avoid systemic toxicities
7.7. Tumor Properties to Consider for Intratumoral Therapies
7.7.1. TME
7.7.2. Intratumoral transport
7.8. Categories of Intratumoral Therapies
7.8.1. Pathogen-associated molecular patterns (PAMPs)
7.8.2. Cytokines
7.8.3. Oncolytic viruses
7.8.4. Cancer gene therapy
7.8.5. Monoclonal antibodies
7.8.6. Small molecules
7.9. Advantages of Intratumoral Therapies
7.10. Limitations of Intratumoral Therapies
7.11. Emerging Therapies and Future Directions
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Epidemiology Scenario in the 7MM
8.3.1. Total Incident cases of selected cancer types across the 7MM
8.3.2. Target Patient Pool of Intratumoral therapies by Cancer Types across the 7MM
8.3.3. Treated cases by Cancer types across the 7MM
8.4. Epidemiology Scenario in the US
8.4.1. Total Incident cases of selected cancer types across the US
8.4.2. Target Patient Pool of Intratumoral therapies by Cancer Types across the US
8.4.3. Treated cases by Cancer Types across the US
8.5. Epidemiology Scenario in EU5
8.5.1. Total Incident cases of selected cancer types across EU5
8.5.2. Target Patient Pool of Intratumoral therapies by Cancer Types across EU5
8.5.3. Treated cases by Cancer Types across EU5
8.6. Epidemiology Scenario in Japan
8.6.1. Total Incident cases of selected cancer types across Japan
8.6.2. Target Patient Pool of Intratumoral therapies by Cancer Types across Japan
8.6.3. Treated cases by Cancer Types across Japan
9. Key Endpoints in Intratumoral Cancer Therapies
10. Marketed Therapies
10.1. Key Cross of Marketed Therapies
10.2. IMLYGIC (talimogene laherparepvec): Amgen
10.2.1. Product description
10.2.2. Regulatory milestones
10.2.3. Other developmental activities
10.2.4. Pivotal clinical trial
10.2.5. Ongoing pipeline activity
10.3. DELYTACT (G47Δ): Daiichi Sankyo
10.3.1. Product description
10.3.2. Regulatory milestones
10.3.3. Other developmental activities
10.3.4. Pivotal clinical trials
11. Emerging Therapies
11.1. Key Cross
11.2. HENSIFY: Nanobiotix
11.2.1. Product description
11.2.2. Other developmental activities
11.2.3. Clinical development
11.2.4. Safety and Efficacy
11.3. STP705 (cotsiranib ): Sirnaomics
11.3.1. Product description
11.3.2. Other developmental activities
11.3.3. Clinical development
11.3.4. Safety and efficacy
11.4. Sotigalimab (APX005M): Apexigen
11.4.1. Product description
11.4.2. Other developmental Activities
11.4.3. Clinical development
11.5. RP1 (Vusolimogene Oderparepvec): Replimune
11.5.1. Product description
11.5.2. Other developmental activities
11.5.3. Clinical development
11.5.4. Safety and efficacy
11.6. V937 (CVA21/CAVATAK): Merck & Co (Viralytics)
11.6.1. Product description
11.6.2. Other developmental activities
11.6.3. Clinical development
11.6.4. Safety and efficacy
11.7. BO-112: Highlight Therapeutics
11.7.1. Product description
11.7.2. Other developmental activities
11.7.3. Clinical development
11.7.4. Safety and efficacy
11.8. TAVO (tavokinogene telseplasmid): OncoSec Medical Incorporated
11.8.1. Product description
11.8.1. Other developmental activities
11.8.2. Clinical development
11.8.3. Safety and efficacy
11.9. INT230-6 (cisplatin/vinblastine): Intensity Therapeutics
11.9.1. Product description
11.9.2. Other developmental activities
11.9.3. Clinical development
11.9.4. Safety and efficacy
11.10. DNX-2401 (tasadenoturev): DNAtrix
11.10.1. Product description
11.10.2. Other developmental activities
11.10.3. Clinical development
11.10.4. Safety and efficacy
11.11. G207: Treovir
11.11.1. Product description
11.11.2. Other developmental activities
11.11.3. Clinical development
11.11.4. Safety and efficacy
11.12. NIDLEGY (daromun; L19IL2 + L19TNF): Philogen
11.12.1. Product Description
11.12.2. Other developmental activities
11.12.3. Clinical development
11.12.4. Safety and efficacy
11.13. LOAd703: Lokon Pharma AB
11.13.1. Product description
11.13.2. Other developmental activities
11.13.3. Clinical development
11.13.4. Safety and efficacy
11.14. Vidutolimod (CMP-001): Regeneron
11.14.1. Product description
11.14.2. Other developmental activities
11.14.3. Clinical development
11.14.4. Safety and efficacy
11.15. Lerapolturev (Formerly Known as PVSRIPO): Istari Oncology
11.15.1. Product description
11.15.2. Other developmental activities
11.15.3. Clinical development
11.15.4. Safety and efficacy
12. Attribute Analysis
13. Intratumoral Cancer Therapies: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Market Size of Intratumoral Cancer Therapies in the 7MM
13.3.1. Total Market Size of Intratumoral Cancer Therapies
13.3.2. Total Market Size of Intratumoral Cancer Therapies by Indications in the 7MM
13.3.3. Market Size of Intratumoral Cancer Therapies by Therapies
13.4. Market Size of Intratumoral Cancer Therapies in the US
13.4.1. Total Market Size of Intratumoral Cancer Therapies
13.4.2. Total Market Size of Intratumoral Cancer Therapies by Indications
13.4.3. Market Size of Intratumoral Cancer Therapies by Therapies in the US
13.5. Market Size of Intratumoral Cancer Therapies in EU5
13.5.1. Total Market Size of Intratumoral Cancer Therapies
13.5.2. Total Market Size of Intratumoral Cancer Therapies by Indications
13.5.3. Market Size of Intratumoral Cancer Therapies by Therapies in EU5
13.6. Market Size of Intratumoral Cancer Therapies in Japan
13.6.1. Total Market Size of Intratumoral Cancer Therapies
13.6.2. Total Market Size of Intratumoral Cancer Therapies by Indications
13.6.3. Market Size of Intratumoral Cancer Therapies by Therapies in Japan
14. Market Access and Reimbursement
14.1. NICE UK
14.2. IQWiG and GBA assessment
14.3. Japan
14.4. Patient assistance programs
14.5. Future Therapy Assessment
15. KOL Views
16. SWOT analysis
17. Unmet Needs
18. Appendix
18.1. Acronyms and Abbreviations
18.2. Bibliography
18.3. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
List of Table
Table 1: Summary of Intratumoral Cancer Therapy: Market, Epidemiology, and Key Events (2019–2032)
Table 2: Factors Affecting Transport of Therapy Out of the Tumor After Intratumoral Injection and Probable Transport Phenomena
Table 3: Categories of Intratumoral Therapies to Treat Cancer
Table 4: Intratumoral Immunotherapy: Universal Rather than Personalized Cancer Immunization
Table 5: Incident cases (2020) and Year-over-year (YOY) cancer growth rates
Table 6: Total incident cases of selected cancer types across the 7MM (2019–2032)
Table 7: Target patient Pool of Intratumoral therapies by Cancer Types across the 7MM (2019–2032)
Table 8: Treated cases by Cancer Types across the 7MM (2019–2032)
Table 9: Total Incident cases of selected cancer types across the US (2019–2032)
Table 10: Target patient Pool of Intratumoral therapies by Cancer Types across the 7MM (2019–2032)
Table 11: Treated cases by Cancer Types across the US (2019–2032)
Table 12: Total Incident cases of selected cancer types across EU5 (2019–2032)
Table 13: Treated cases by Cancer Types across EU5 (2019–2032)
Table 14: Total Incident cases of selected cancer types in Japan (2019–2032)
Table 15: Target patient Pool of Intratumoral therapies by Cancer Types in Japan (2019–2032)
Table 16: Treated cases by Cancer Types in Japan (2019–2032)
Table 17: Summary of Results for the ITT Population From IMLYGIC Study 005/05
Table 18: IMLYGIC, Clinical Trial Description, 2022
Table 19: Results on Tumor Reduction Effect and Safety
Table 20: HENSIFY (NBTXR3), Clinical Trial Description, 2022
Table 21: STP705; Clinical Trial Description, 2022
Table 22: APX005M; Clinical Trial Description, 2022
Table 23: RP1; Clinical Trial Description, 2022
Table 24: V937; Clinical Trial Description, 2022
Table 25: BO-112, Clinical Trial Description, 2022
Table 26: Tavokinogene telseplasmid (tavo); Clinical Trial Description, 2022
Table 27: INT230-6; Clinical Trial Description, 2022
Table 28: DNX-2401; Clinical Trial Description, 2022
Table 29: G207; Clinical Trial Description, 2022
Table 30: NIDLEGY (daromun; L19IL2 + L19TNF), Clinical Trial Description, 2022
Table 31: LOAd703, Clinical Trial Description, 2022
Table 32: Vidutolimod (CMP-001); Clinical Trial Description, 2022
Table 33: PVSRIPO; Clinical Trial Description, 2022
Table 34: 7MM Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 35: 7MM Market Size of Intratumoral Cancer Therapies By Indications in USD Million (2019–2032)
Table 36: 7MM Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 37: US Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 38: US Market Size of Intratumoral Cancer Therapies By Indications in USD Million (2019–2032)
Table 39: US Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 40: EU5 Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 41: EU5 Market Size of Intratumoral Cancer Therapies By Indications in USD Million (2019–2032)
Table 42: EU-5 Market Size of Intratumoral Cancer Therapies by Therapies in USD Million (2018–2032)
Table 43: Japan Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 44: Japan Market Size of Intratumoral Cancer Therapies By Indications in USD Million (2019–2032)
Table 45: Japan Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 46: NICE Assessment for Intra-tumoral Therapies
List of Figures
Figure 1: Types of Cancer Treatment
Figure 2: Timeline for Intratumoral Immunotherapy
Figure 3: Intratumoral Immunotherapy Mechanisms and Invoking an Abscopal Effect
Figure 4: Principles of Intratumoral Immunotherapy
Figure 5: Classification of the Different Types of Immunotherapy Agents
Figure 6: Global Heat Map of all cancers in 2020, both sexes, all ages
Figure 7: Total incident cases of selected cancer types across the 7MM (2019–2032)
Figure 8: Target patient Pool of Intratumoral therapies by Cancer Types across the 7MM (2019–2032)
Figure 9: Treated cases by Cancer Types across the 7MM (2019–2032)
Figure 10: Total Incident cases of selected cancer types across the US (2019–2032)
Figure 11: Target patient Pool of Intratumoral therapies by Cancer Types across the US (2019–2032)
Figure 12: Treated cases by Cancer Types in the US (2019–2032)
Figure 13: Total Incident cases of selected cancer types in EU5 (2019–2032)
Figure 14: Target patient Pool of Intratumoral therapies by Cancer Types across EU5 (2019–2032)
Figure 15: Treated cases by Cancer Types across EU5 (2019–2032)
Figure 16: Total Incident cases of selected cancer types in Japan (2019–2032)
Figure 17: Target patient Pool of Intratumoral therapies by Cancer Types in Japan (2019–2032)
Figure 18: Treated cases by Cancer Types across the 7MM in Japan (2018–2032)
Figure 19: Intratumoral Immunotherapy Clinical Trials
Figure 20: Mechanism of Action
Figure 21: Structure of DNX-2401 (tasadenoturev)
Figure 22: Market Size of Intratumoral Cancer Therapies in the 7MM, USD Million (2019–2032)
Figure 23: Market Size of Intratumoral Cancer Therapies By Indications in the 7MM, USD Million (2019–2032)
Figure 24: 7MM Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Figure 25: Market Size of Intratumoral Cancer Therapies in the US, USD Million (2019–2032)
Figure 26: Market Size of Intratumoral Cancer Therapies By Indications in the US, USD Million (2019–2032)
Figure 27: US Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Figure 28: Market Size of Intratumoral Cancer Therapies in EU5, USD Million (2019–2032)
Figure 29: Market Size of Intratumoral Cancer Therapies By Indications in the EU5, USD Million (2019–2032)
Figure 30: EU5 Therapywise market size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Figure 31: Market Size of Intratumoral Cancer Therapies in Japan, USD Million (2019–2032)
Figure 32: Market Size of Intratumoral Cancer Therapies By Indications in Japan, USD Million (2019–2032)
Figure 33: Japan Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Nanobiotix
Sirnaomics
Apexigen
Replimune
Merck & Co (Viralytics)
Highlight Therapeutics
OncoSec Medical Incorporated
Intensity Therapeutics
DNAtrix
Treovir
Philogen
Lokon Pharma AB
Regeneron
Istari Oncology
Amgen
Daiichi Sankyo